Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability

Paul Germonpré; Tim Van den Wyngaert

doi:10.1371/journal.pone.0215135

Loading metrics

Open Access

Peer-reviewed

Research Article

Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability

Paul Germonpré,

Roles Conceptualization, Funding acquisition, Methodology, Writing – review & editing

Affiliations Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium, Department of Pneumology, AZ Maria Middelares, Ghent, Belgium
⨯
Tim Van den Wyngaert

Roles Data curation, Formal analysis, Writing – original draft, Writing – review & editing

* E-mail: tim.van.den.wyngaert@uza.be

Affiliations Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium, Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium

http://orcid.org/0000-0002-0320-9075

⨯

Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability

Paul Germonpré,
Tim Van den Wyngaert

Published: April 11, 2019
https://doi.org/10.1371/journal.pone.0215135

About the Authors

Paul Germonpré

Roles Conceptualization, Funding acquisition, Methodology, Writing – review & editing

Affiliations Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium, Department of Pneumology, AZ Maria Middelares, Ghent, Belgium

Tim Van den Wyngaert

Roles Data curation, Formal analysis, Writing – original draft, Writing – review & editing

* E-mail: tim.van.den.wyngaert@uza.be

Affiliations Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium, Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium

http://orcid.org/0000-0002-0320-9075

Competing Interests

The authors have declared that no competing interests exist.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Rashes
Is the Subject Area "Rashes" applicable to this article?

Thanks for your feedback.
Cancer chemotherapy
Is the Subject Area "Cancer chemotherapy" applicable to this article?

Thanks for your feedback.
Diarrhea
Is the Subject Area "Diarrhea" applicable to this article?

Thanks for your feedback.
Chemotherapy
Is the Subject Area "Chemotherapy" applicable to this article?

Thanks for your feedback.
Intravenous injections
Is the Subject Area "Intravenous injections" applicable to this article?

Thanks for your feedback.